Power Law company profile

I-Mab Biopharma

Biotech & Life Sciences · Huangpu, China · Founded 2016 · IPO 2020 Unicorn

I-Mab is a dynamic, global biotech company exclusively focused on discovery, development and soon commercialization of novel or highly differentiated biologics in the therapeutic areas of immuno-oncology and autoimmune diseases

Valuation

$272M

Market cap · 2026

Featured in Unicorn$1B+ valuation tier · Power Law dataset 2026 $10B+ revenueThoroughbred · Power Law outcome

Investors

20 investors on I-Mab Biopharma's cap table

Sourced from Dealroom's funding history. Investor profile links are shown where available.

Series A 2 investors entered at this stage

CBC Group

Cambridge Capital

Series B+ 18 investors entered at this stage

Lake Bleu Capital

Sphera Global Healthcare Fund

Perceptive Advisors

OrbiMed

Genexine

HOPU Fund

Tally Capital

Invus

Hillhouse Capital

Octagon Capital Partners

Ally Bridge Group

Tasly Pharmaceutical

Hony Capital

EDBI

C-Bridge Capital

VMS Group

GIC

CDH Investments

Global footprint

Where I-Mab Biopharma has talent and traffic

Workforce by country

3 countries with
team presence

🇨🇳 China70.3%

🇺🇸 United States26.2%

🇭🇰 Hong Kong3.4%

3 countries shown

Web traffic by country

130 monthly visits
across markets

🇺🇸 United States76.9%

Top 1 markets shown

Patent intelligence

$161M patent portfolio · 93 active families

Estimated portfolio value

$161M

59.2% of market cap · 2.3× smaller than top peer Translate Bio ($371M)

93 active patent families

Where I-Mab Biopharma innovates Molecular biologyAntiendomysial antibodiesAnti antibodyPharmaceutical drugL1

Where I-Mab Biopharma concentrates vs peers

Each axis is a top-10 topic across I-Mab Biopharma and its closest peers. #1 = 100, #10 = 10, absent = 0.

Compare against

Source: Dealroom Patent Intelligence · Patsnap. Request a demo for the full per-sub-category breakdown, individual records, and quality-score history.

Market sentiment

What the market is saying about I-Mab Biopharma

An AI-synthesized read of the highest-engagement posts about I-Mab Biopharma on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See I-Mab Biopharma on the full Dealroom platform

Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.

Book a demo Explore company profiles